Description
Anti-Complement C3b Antibody, Non-Fucosylated (BioBet-614ZP) is a humanized monoclonal IgG antibody against Complement C3b. This product is an ADCC enhanced antibody produced by our Afuco™ platform.
Antibody Indication
Complement-associated Disorder
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced Complement C3b antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
C3
Full Name
complement component 3
Background
Complement component C3 plays a central role in the activation of complement system. Its activation is required for both classical and alternative complement activation pathways. A peptide (C3a) derived from the encoded protein has antimicrobial activity, so people with C3 deficiency are susceptible to bacterial infection.
Alternative Names
C3; complement component 3; ASP; C3a; C3b; AHUS5; ARMD9; CPAMD1; HEL-S-62p; complement C3; prepro-C3; C3a anaphylatoxin; complement component C3; complement component C3a; complement component C3b; acylation-stimulating protein cleavage product; epididymis secretory sperm binding protein Li 62p; C3 and PZP-like alpha-2-macroglobulin domain-containing protein 1
Gene ID
718
Cellular Localization
Extracellular region or secreted
Involvement in Disease
Diseases associated with C3 include Complement Component 3 Deficiency, Autosomal Recessive and Hemolytic Uremic Syndrome, Atypical 5.
Related Pathways
Its related pathways are Immune response Lectin induced complement pathway and Signaling by GPCR.
Function
C3 plays a central role in the activation of the complement system. Its processing by C3 converting enzyme is the central reaction in the classical and alternative complement pathway. After activation, C3b can covalently bind cell surface carbohydrates or immune aggregates through its reactive thioester. Type C3a anaphylactic shock toxin is derived from the proteolytic degradation of complement C3 and is the mediator of local inflammation. In chronic inflammation, as a chemotactic agent for neutrophils (similar). It induces smooth muscle contraction, increases vascular permeability, and causes histamine to be released from mast cells and basophils.
Post-translational modifications
C3b is rapidly split in two positions by factor I and a cofactor to form iC3b (inactivated C3b) and C3f which is released. Then iC3b is slowly cleaved (possibly by factor I) to form C3c (beta chain + alpha' chain fragment 1 + alpha' chain fragment 2), C3dg and C3f. Other proteases produce other fragments such as C3d or C3g. C3a is further processed by carboxypeptidases to release the C-terminal arginine residue generating the acylation stimulating protein (ASP). Levels of ASP are increased in adipocytes in the postprandial period and by insulin and dietary chylomicrons. Phosphorylated by FAM20C in the extracellular medium.
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG
Antibody Clone
BioBet-614ZP
Description
This is an anti-C3b antibody containing various combinations of complementarity determining regions 1 through 3 (CDRs 1 through 3), and framework regions (FR1 through FR4). The the framework regions are used for the treatment of disease conditions for which alternative complement pathway plays a role.
Antibody Indication
Complement-associated Disorder
Complement-associated Disorder
